The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion
| Autor: | Marat V. Ezhov, Angela Pirillo, Lars Ellegård, Andrea Poli, Günter Silbernagel, Olivier S. Descamps, György Paragh, Demosthenes B. Panagiotakos, Alberico L. Catapano, Maciej Banach, Daniel Pella, Michal Vrablík, Zlatko Fras, Petri T. Kovanen, Bernhard Föger, Eric Bruckert, Željko Reiner, Winfried März, Margus Viigimaa, Gustavs Latkovskis |
|---|---|
| Přispěvatelé: | UCL - (SLuc) Service de pathologie cardiovasculaire, Medical University of Łódź (MUL), University of Zielona Góra, Institut E3M [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Cliniques Universitaires Saint-Luc [Bruxelles], Sahlgrenska Academy at University of Gothenburg [Göteborg], Innsbruck Medical University [Austria] (IMU), University of Ljubljana, University of Latvia (LU), Medical University Graz, University of Heidelberg, Medical Faculty, Harokopio University of Athens, University of Debrecen, Pavol Jozef Šafárik University, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), University of Zagreb, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), German Center for Cardiovascular Research (DZHK), Tallinn University of Technology (TTÜ), Charles University [Prague] (CU), University of Milan, Gestionnaire, Hal Sorbonne Université, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), University of Debrecen Egyetem [Debrecen], Università degli Studi di Milano = University of Milan (UNIMI) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Gastrointestinal Diseases
[SDV]Life Sciences [q-bio] Hypercholesterolemia Self Medication 030204 cardiovascular system & hematology Pharmacology 03 medical and health sciences Food-Drug Interactions 0302 clinical medicine Plasma cholesterol Biotransformation Double-Blind Method Chinese traditional Internal Medicine Red yeast rice Medicine Cytochrome P-450 CYP3A Humans Multicenter Studies as Topic Prodrugs 030212 general & internal medicine Lovastatin Musculoskeletal Diseases Medicine Chinese Traditional Expert Testimony ComputingMilieux_MISCELLANEOUS Randomized Controlled Trials as Topic Biological Products Clinical Trials as Topic Molecular Structure Ryanodine receptor business.industry General Medicine 3. Good health Cholesterol blood [SDV] Life Sciences [q-bio] Cholesterol Cardiovascular Diseases Expert opinion Dietary Supplements lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business |
| Zdroj: | Atherosclerosis. Supplements, Vol. 39, p. e1-e8 (2019) ''Atherosclerosis Supplements'' ''Atherosclerosis Supplements'', 2019, ⟨10.1016/j.atherosclerosissup.2019.08.023⟩ |
| DOI: | 10.1016/j.atherosclerosissup.2019.08.023⟩ |
| Popis: | 1. Preamble : Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) [1]. Increased levels of low density lipoprotein cholesterol (LDL-C) are associated with an increased risk of coronary heart disease (CHD) and many clinical trials have shown that reducing LDL-C levels significantly reduced the CHD and CVD risk [[2], [3], [4], [5]]. Thus LDL-C-lowering is the main approach for the management of cardiovascular disease. Current guidelines suggest LDL-C levels targets based on the individual CV risk; such targets can be achieved by several means, which include both lifestyle changes and pharmacological approaches [6], with statins being the cornerstone of cardiovascular prevention. [...] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|